Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)]
1 Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany.
2 Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany; Department of Nephropathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
3 Dr. Senckenberg Institute of Pathology (SIP), University Hospital Frankfurt & Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt, Germany.
4 Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
5 Department of Pathology, Medical University of Vienna, Vienna, Austria.
6 Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, Cordoba, Spain.
7 Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy.
8 Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA; The Legorreta Cancer Center at Brown University, Providence, RI, USA.
9 Laboratory Medicine Program, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
10 Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
11 Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
12 Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA.
13 Department of Pathology and Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
14 Urologische Gemeinschaftspraxis Prüner Gang, Kiel, Germany; Department of Urology, Städtisches Krankenhaus Kiel, Kiel, Germany.
15 Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.
16 Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Electronic address: simone.bertz@uk-erlangen.de.